Business Overview
MiniMed Group, Inc. is a scaled global medical technology company that develops, manufactures, and markets comprehensive diabetes management solutions, including automated insulin delivery (AID) systems, continuous glucose monitors (CGMs), and smart multiple daily injection systems. The company is executing on launches of second and third-generation AID systems, including the MiniMed Flex insulin pump (FDA cleared March 2026, launched June 2026) and next-generation Vivera dosing algorithm in pivotal trials. In fiscal year 2026, MiniMed generated $3.1 billion in revenue (up from $2.7 billion in fiscal 2025), with approximately 70% derived from outside the United States.
Forward Guidance
"Our market is expected to grow at a compound annual growth rate above 10% from 2026 through at least 2030, according to Seagrove Partners March 2026 market model, driven by the adoption of advanced diabetes management technologies." The company states it "aim[s] to achieve profitable growth" and indicates plans to "submit MiniMed Fit patch pump with extended wear for U.S. FDA approval by fall of calendar year 2026, with CE Mark submission thereafter." Forward-looking statements also reference expectations regarding "continued or future acceptance of products, therapies, and services," "expected timing for completion of research studies," and "anticipated timing for U.S. FDA and non-U.S. regulatory approval or clearance of new products."
Key Risk Factors
Key risks include: (1) intense competitive pressure and potential product obsolescence as competing technologies emerge; (2) supply chain vulnerabilities, including reliance on sole suppliers and manufacturing difficulties with the Simplera CGM and other products; (3) regulatory and reimbursement risks, including coverage uncertainties and pricing pressures; (4) limited standalone operating history following separation from Medtronic, with substantial ongoing separation and integration costs; (5) Medtronic's continued control as a majority shareholder, which may restrict business decisions and impact stock valuation.
